Biotron was a big mover after announcing the establishment of an expert Scientific Advisory Board. The board is tasked with the responsibility of spearheading and overseeing the upcoming Phase 2 HIV-1 clinical development program.
Chaired By professor Robert L Murphy, the board includes an international group of experts with vast experience in matters pertaining to HIV-1 as well as clinical development of HIV-1 therapies. The formation of the board comes hot on the heels of the company reporting positive results as part of BIT225-009 phase 2 HIV-1 clinical trial.
Chaired By professor Robert L Murphy, the board includes an international group of experts with vast experience in matters pertaining to HIV-1 as well as clinical development of HIV-1 therapies. The formation of the board comes hot on the heels of the company reporting positive results as part of BIT225-009 phase 2 HIV-1 clinical trial.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。